International Atherosclerosis Society
doi: 10.3389/fimmu.2025.1578940 Received 18 February 2025 Accepted 24 March 2025 Published 10 April 2025 Volume 16 - 2025 Edited by Fabrizio Fontana, University of Milan, Italy Reviewed by Bjrn Steen Sklhegg, University of Oslo, Norway Josephine Anthony, Meenakshi Academy of Higher Education and Research, India Updates Copyright 2025 Fang, Gao, Jiang, Li and Li
This opens the door for potential pharmacological manipulation to enhance antioxidant delivery
Moisturizing and soothing skin
The legality concern applies to the seller, not the buyerif the manufacturer markets the product with prohibited disease claims or the formulation is adulterated, the FDA targets the company, not individual consumers
Due to the compound's plasma half-life of approximately 3.86.9 hours [4] , twice-daily (BID) dosing may provide more sustained NNMT inhibition